Metrikler
Yayın
43
Açık Erişim
3
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (20)
SCI-E, SSCI, AHCI (16)
SCI-E, SSCI, AHCI, ESCI (17)
ESCI (1)
Scopus (17)
TRDizin (3)
2025
20251. Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project
PINAR İ. E., ÇELİK S., Polat M. G., Karatas A. F., Doğan A., ILTAR U., et al.
BMC Cancer
, cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)
2023
20232. The Tip of the Iceberg: Vaginal Bleeding and Granulocytic Sarcoma of the Uterus
Celik S., Guven Z. T., YILDIRIM T., KAYNAR L., ESER B., Cetin M., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, cilt.23, ss.273, 2023 (SCI-Expanded, Scopus)
2023
20233. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
Dal M. S., Ulu B. U., UZAY A., Akay O. M., Besisik S., Yenerel M. N., et al.
ANNALS OF HEMATOLOGY
, cilt.102, sa.1, ss.133-140, 2023 (SCI-Expanded, Scopus)
2022
20224. COVID-19 in hematopoietic stem-cell transplantation recipients: Single center experience
Guven Z. T., Celik S., Keklik M., Unal A.
BONE MARROW TRANSPLANTATION
, cilt.57, sa.SUPPL 1, ss.290-291, 2022 (SCI-Expanded, Scopus)
2022
20225. Secondary hypogammaglobulinemia in cll
Unal A., Fidan K., Keklik M., Celik S., Baydar M., Sanli N. M., et al.
BONE MARROW TRANSPLANTATION
, cilt.57, sa.SUPPL 1, ss.306-307, 2022 (SCI-Expanded, Scopus)
2022
20226. Does HLA tissue group change after granulocyte transfusion?
Unal A., Baydar M., KÖKER M. Y., Keklik M., Fidan K., Guven Z. T., et al.
BONE MARROW TRANSPLANTATION
, cilt.57, sa.SUPPL 1, ss.416, 2022 (SCI-Expanded, Scopus)
2022
20227. Evaluation of refeeding hypophosphatemia frequency, risk factors, and nutritional status during stem cell transplantation in patients with hematologic malignancy
Ergül S. Ş., Sahin G. G., Ozer N. T., Kaynar L., Celik S., GÜNDOĞAN K.
Clinical Nutrition ESPEN
, cilt.51, ss.385-390, 2022 (ESCI, Scopus)
2022
20228. One-Year Follow-Up of Cystic Fibrosis Patients Who Cannot Reach the Modulator Therapies Although Having Indications: What are Their Losses?
Uytun S., Polat S. E., Tabakci S. O., Cinel G., EMİRALİOĞLU ORDUKAYA N., Yalcin E., et al.
EUROPEAN RESPIRATORY JOURNAL
, cilt.60, 2022 (SCI-Expanded, Scopus)
2022
20229. Comparison of centrifugal and membrane filtration modalities on therapeutic plasma exchange
KEKLİK M., ÇELİK S., Yildizhan E.
JOURNAL OF CLINICAL APHERESIS
, cilt.37, sa.3, ss.217-222, 2022 (SCI-Expanded, Scopus)
2022
202210. Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study
Artac M., Cubukcu E., Bozkurt O., Bilici A., Celik S., Ozcelik M., et al.
ANNALS OF ONCOLOGY
, cilt.33, 2022 (SCI-Expanded, Scopus)
2022
202211. Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy
ÇELİK S., KAYNAR L., GÜVEN Z. T., BAYDAR M., KEKLİK M., ÇETİN M., et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
, cilt.38, sa.2, ss.282-289, 2022 (SCI-Expanded, Scopus)
2022
202212. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
Akpinar S., Dogu M. H., ÇELİK S., Ekinci O., Hindilerden I. Y., Dal M. S., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, cilt.22, sa.3, ss.169-173, 2022 (SCI-Expanded, Scopus)
2021
202113. Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy
KARASU N., Akalin H., GÖKÇE N., YILDIRIM A., DEMİR M., Kulak H., et al.
MEDICAL ONCOLOGY
, cilt.38, sa.10, 2021 (SCI-Expanded, Scopus)
2021
202114. Retrospective evaluation of patients with primary mediastinal large B-Cell lymphoma: Real life experience
Guven Z., Celik S., Kaynar L., Keklik M., Eser B., Cetin M., et al.
Annals of Medical Research , cilt.28, sa.10, ss.1830-1834, 2021 (TRDizin)
2021
202115. Immune trombocytic purpura during the course of COVID-19 disease:three cases report
FİDAN K., ÜNAL A., KEKLİK M., AKYOL G., BAYDAR M., ÇELİK S., et al.
EUROPEAN JOURNAL OF IMMUNOLOGY
, cilt.51, ss.329, 2021 (SCI-Expanded, Scopus)
2021
202116. A case of primary hemophagocytic syndrome seen in adult age
FİDAN K., KEKLİK M., Sanli N. M., AKYOL G., BAYDAR M., ÇELİK S., et al.
EUROPEAN JOURNAL OF IMMUNOLOGY
, cilt.51, ss.337, 2021 (SCI-Expanded, Scopus)
2021
202117. Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study
Arslan C., Kefeli U., Yildirim E., Isikdogan A., Karadurmus N., Karabulut B., et al.
ANNALS OF ONCOLOGY
, cilt.32, 2021 (SCI-Expanded, Scopus)
2021
202118. Hematopoetik Kök Hücre Nakli Sırasında Gelişen Epileptik Nöbetlerin Değerlendirilmesi: Tek Merkez Deneyimi
ÇELİK S., GÜVEN Z. T., KEKLİK M., KAYNAR L., ESER B., ÇETİN M., et al.
Acta Oncologica Turcica
, cilt.51, sa.1, ss.40-50, 2021 (TRDizin)
2020
202019. Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma
Keklik M., Karakus E., Kaynar L., Akyol G., Guven Z., Celik S., et al.
TRANSFUSION AND APHERESIS SCIENCE
, cilt.59, sa.5, 2020 (SCI-Expanded, Scopus)
2019
201920. Kemoterapi Almış Hematolojik Maligniteli Hastalarda CMV PCR Takibinin Önemi
GÜVEN Z. T., DÜNDAR T., ÇELİK S., KAYNAR L.
LLM Dergi
, cilt.3, sa.3, ss.60-66, 2019 (TRDizin)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2022
20221. Retrospective Analysis of Turkish AML Registry Database, on Behalf of AML Working Group of Turkish Society of Hematology
Karakus V., Sevindik Ö. G., Karatas A., Yenihayat E. M., Polat M. G., Çelik S., et al.
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, ss.8946-8947, (Özet Bildiri)
2021
20212. Immune trombocytic purpura during the course of COVID‐19 disease:three cases report
FİDAN K., ÜNAL A., KEKLİK M., AKYOL G., BAYDAR M., ÇELİK S., et al.
6 th European Congress of Immunology, Online Kongre, Türkiye, 1 - 04 Eylül 2021, cilt.51, ss.329, (Tam Metin Bildiri)
2020
20203. AKUT PROMİYELOSİTİK LÖSEMİ HASTALARINDA ATRAVE ARSENİK İLE ATRA VE İDARUBİSİN TEDAVİLERİNİNKARŞILAŞTIRILMASI
ÇELİK S., ÜNAL A., ŞAHİN R., GÜVEN Z. T., BAYDAR M., KEKLİK M., et al.
46.Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020, ss.86-87, (Tam Metin Bildiri)
2020
20204. SECONDARY HYPOGAMMAGLOBULINEMIA INPATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIARECEIVING IBRUTINIB THERAPY
Çelik S., Güven Z. T., Ünal A., Kaynar L.
25th Congress of theEuropean HematologyAssociation, 11 - 22 Haziran 2020, ss.874, (Özet Bildiri)
2020
20205. GASTROINTESTINAL PLASMOBLASTIC LYMPHOMAASSOCIATED WITH WISKOTT-ALDRICH SYNDROME: A CASEREPORT
ÜNAL A., ÇELİK S., GÜVEN Z. T., KAYNAR L., ESER B., KONTAŞ O., et al.
25th Congress of the European Hematology Association Virtual Congress, 11 - 22 Haziran 2020, ss.1014, (Özet Bildiri)
2020
20206. EVALUATION OF PATIENTS WITH ADULT ONSETLANGERHANS CELL HISTIOCYTOSIS: A SINGLE CENTEREXPERIENCE
ÜNAL A., ÇELİK S., GÜVEN Z. T., AŞIK O., KAYNAR L., ESER B., et al.
25th Congress of theEuropean Hematology Association Virtual Congress, 11 - 22 Haziran 2020, ss.992, (Özet Bildiri)
2020
20207. AKUT LÖSEMİDE İN VİTRO T HÜCRE DEPLESYONU VE NAKİL SONRASI SİKLOFOSFAMİDLE YAPILAN HAPLOİDENTİKNAKİL SONUÇLARIMIZ
GÜVEN Z. T., KAYNAR L., ÇELİK S., KEKLİK M., ÜNAL A., ÇETİN M.
12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, ss.61-62, (Tam Metin Bildiri)
2020
20208. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI NADİR BİRKOMPLİKASYON: ASPERGİLLUS OSTEOMİYELİTİ
ÇELİK S., CİVAN M., GÜVEN Z. T., KAYNAR L.
12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, ss.95, (Tam Metin Bildiri)
2019
20199. HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASITROMBOSİTOPENİ TEDAVİSİNDE ELTROMBOPAGKULLANIMI TEK MERKEZ DENEYİMİ
GÜVEN Z. T., ÇELİK S., KAYNAR L., ÇETİN M., ÜNAL A.
45. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 31 Ekim - 02 Kasım 2019, (Tam Metin Bildiri)
2019
201910. EVALUATION OF PATIENTS WITH ADULT ONSET LANGERHANS CELLHISTIOCYTOSIS: A SINGLE CENTER EXPERIENCE
ÇELİK S., GÜVEN Z. T., AŞIK O., KAYNAR L., ÇETİN M., ÜNAL A.
AHOS 2019, 3 - 06 Ekim 2019, (Tam Metin Bildiri)
2019
201911. Single Center Experience: Retrospective Evaluation of Patientswith Primary Mediastinal Large B-Cell Lymphoma
GÜVEN Z. T., ÇELİK S., KAYNAR L., ÇETİN M., ÜNAL A.
AHOS 2019, 3 - 06 Ekim 2019, (Tam Metin Bildiri)
2019
201912. INVESTIGATION OF THE EFFECTS OF ANTIFUNGAL DRUGS ON CYCLOSPORIN BLOOD LEVEL IN PATIENTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
GÜNAY A., GÜVEN Z. T., ÇELİK S., DEMİRPOLAT E., MÜKERREM B. A., KAYNAR L., et al.
6th AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM, İzmir, Türkiye, 3 - 06 Ekim 2019, (Özet Bildiri)
2019
201913. A VERY RARE CASE OF HEMOGLOBINOPATHY: HBS-BETA THALASSEMIA DISEASE
KARACA E., ÇELİK S., GÜVEN Z. T., KAYNAR L., ÇETİN M., ÜNAL A., et al.
6TH AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM, İzmir, Türkiye, 3 - 06 Ekim 2019, ss.121, (Tam Metin Bildiri)
2019
201914. Is prescribing acid suppressive drugs for every patient is a good decision: a pH plus all case report
GÜNAY A., GÜVEN Z. T., ÇELİK S., ÇETİN M., AYCAN M. B., DEMİRPOLAT E., et al.
10th Eurasian Hematology Oncology Congress, İstanbul, Türkiye, 8 - 11 Ekim 2019, cilt.85, (Özet Bildiri)
2019
201915. Successful treatment of relapsed and refractory cold agglutinin disease with bortezomib: case report
ÇELİK S., GÜVEN Z. T., ESER B., KAYNAR L., ÇETİN M., ÜNAL A.
10th Eurasian Hematology Oncology Congress, İstanbul, Türkiye, 8 - 11 Ekim 2019, cilt.85, (Özet Bildiri)
2019
201916. Gastrointestinal plasmoblastic lymphoma associated with Wiskott-Aldrich syndrome: a case report
ÜNAL A., ÇELİK S., GÜVEN Z. T., KAYNAR L., ESER B., ÇETİN M.
10th Eurasian Hematology Oncology Congress, İstanbul, Türkiye, 8 - 11 Ekim 2019, cilt.85, (Özet Bildiri)
2019
201917. Evaluation of secondary hypogammaglobulinemia in patients with hematologic malignancy receiving ibrutinib therapy
ÇELİK S., GÜVEN Z. T., KAYNAR L., ESER B., ÇETİN M., ÜNAL A.
10th Eurasian Hematology Oncology Congress, İstanbul, Türkiye, 8 - 11 Ekim 2019, cilt.85, (Özet Bildiri)
2019
201918. Successful haploidentic bone marrow transplantation with inotuzumab ozogamicin in patient with relapsed and resistant B cell acute lymphoblastic leukemia
Ünal A., Çelik S., Güven Z. T., Eser B., Kaynar L., Çetin M.
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.523-524, (Özet Bildiri)
2019
201919. Can long non-coding RNA HOTAIR be a novel biomarker in the diagnosis of CML
BENTLİ E., AKBAROVA Y., AKALIN H., TAŞCIOĞLU N., SARAYMEN B., ÇETİN M., et al.
VI.Uluslararası Katılımlı Deneysel Hematoloji Kongresi, Türkiye, 19 - 21 Nisan 2019, (Özet Bildiri)
2019
201920. Molecular Analysis of Hotspot Mutation Sites in Chronic Myeloid Leukemia (CML) Patients with Imatinib Mesylate Drug Resistance
KARASU N., Akalın H., GÖKÇE N., ÇELİK S., ESER B., DÜNDAR M.
Uluslararası 7. İlaç Kimyası: İlaç Etkin Maddesi Tasarımı, Sentezi, Üretimi ve Standardizasyonu Kongresi, Antalya, Türkiye, 14 - 17 Mart 2019, cilt.1, ss.1, (Tam Metin Bildiri)